These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors. Jackson A; Taylor S; Boffito M AIDS Rev; 2004; 6(4):208-17. PubMed ID: 15700619 [TBL] [Abstract][Full Text] [Related]
4. Protease inhibitor plasma concentrations in HIV antiretroviral therapy. Justesen US Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158 [TBL] [Abstract][Full Text] [Related]
5. Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes. Luber AD AIDS Read; 2005 Dec; 15(12):692-5, 698-700. PubMed ID: 16355599 [TBL] [Abstract][Full Text] [Related]
6. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. Youle M J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281 [TBL] [Abstract][Full Text] [Related]
7. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy. van Lunzen J; Liess H; Arastéh K; Walli R; Daut B; Schürmann D HIV Med; 2007 May; 8(4):220-5. PubMed ID: 17461849 [TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy in AIDS patients with tuberculosis. Moreno S; Hernández B; Dronda F AIDS Rev; 2006; 8(3):115-24. PubMed ID: 17078482 [TBL] [Abstract][Full Text] [Related]
9. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients. Ortega KL; Vale DA; Magalhães MH J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845 [TBL] [Abstract][Full Text] [Related]
10. Interactions between recreational drugs and antiretroviral agents. Antoniou T; Tseng AL Ann Pharmacother; 2002 Oct; 36(10):1598-613. PubMed ID: 12243611 [TBL] [Abstract][Full Text] [Related]
11. Common HIV drug-drug interactions. O'Brien LW AIDS Read; 1999; 9(2):104-9. PubMed ID: 12728892 [TBL] [Abstract][Full Text] [Related]
12. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Jiménez-Nácher I; Alvarez E; Morello J; Rodriguez-Nóvoa S; de Andrés S; Soriano V Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):457-77. PubMed ID: 21342079 [TBL] [Abstract][Full Text] [Related]
13. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. Mounier N; Katlama C; Costagliola D; Chichmanian RM; Spano JP Crit Rev Oncol Hematol; 2009 Oct; 72(1):10-20. PubMed ID: 19070506 [TBL] [Abstract][Full Text] [Related]
14. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients? Cuzin L; Allavena C; Morlat P; Dellamonica P AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976 [TBL] [Abstract][Full Text] [Related]
15. Acid suppressive therapy and the effects on protease inhibitors. Fulco PP; Vora UB; Bearman GM Ann Pharmacother; 2006 Nov; 40(11):1974-83. PubMed ID: 17077173 [TBL] [Abstract][Full Text] [Related]
16. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV. Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091 [TBL] [Abstract][Full Text] [Related]